International Journal of Biological Sciences,
Год журнала:
2024,
Номер
20(14), С. 5747 - 5763
Опубликована: Окт. 21, 2024
Bone
metastasis
is
a
common
cause
of
death
in
patients
with
non-small
cell
lung
cancer
(NSCLC),
approximately
30-40%
NSCLC
eventually
developing
bone
metastases.
metastasis,
especially
the
occurrence
skeletal-related
events
(SREs),
significantly
reduces
overall
survival
(OS)
and
quality
life
(QoL)
patients.
Although
bone-targeting
agents
(BTAs)
have
been
shown
to
reduce
SREs
improve
QoL
metastases,
prognosis
for
these
remains
poor.
Understanding
underlying
molecular
pathways
crucial
development
novel
therapeutic
approaches.
complex,
multistep
process
that
involves
interactions
between
tumor
cells
microenvironment.
The
microenvironment
provides
fertile
soil
cells,
crosstalk
among
various
signaling
secreted
factors
also
plays
role
regulating
progression
NSCLC.
In
this
article,
we
provide
comprehensive
review
process,
regulatory
mechanisms,
clinical
treatment
hope
assisting
treatment.
Journal of Personalized Medicine,
Год журнала:
2024,
Номер
14(7), С. 723 - 723
Опубликована: Июль 4, 2024
Breast
cancer
remains
the
most
prevalent
among
women
worldwide,
driving
urgent
need
for
innovative
approaches
to
diagnosis
and
treatment.
This
review
highlights
pivotal
role
of
nanoparticles
in
revolutionizing
breast
management
through
advancements
interconnected
including
targeted
therapy,
imaging,
personalized
medicine.
Nanoparticles,
with
their
unique
physicochemical
properties,
have
shown
significant
promise
addressing
current
treatment
limitations
such
as
drug
resistance
nonspecific
systemic
distribution.
Applications
range
from
enhancing
delivery
systems
sustained
release
developing
diagnostic
tools
early
precise
detection
metastases.
Moreover,
integration
into
photothermal
therapy
synergistic
use
existing
treatments,
immunotherapy,
illustrate
transformative
potential
care.
However,
journey
towards
clinical
adoption
is
fraught
challenges,
chemical
feasibility,
biodistribution,
efficacy,
safety
concerns,
scalability,
regulatory
hurdles.
delves
state
nanoparticle
research,
applications
diagnosis,
obstacles
that
must
be
overcome
integration.
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 17, 2025
Breast
cancer
causes
the
deaths
of
approximately
685,000
women
annually,
posing
a
severe
threat
to
women's
health.
Consequently,
there
is
an
urgent
need
for
low-cost,
low-toxicity
and
effective
therapeutic
methods
prevent
or
mitigate
breast
progression.
PDBP
are
natural,
non-toxic,
affordable
substances
have
demonstrated
excellent
anti-breast
activities
in
inhibiting
proliferation,
migration,
invasion,
promoting
apoptosis
both
vitro
vivo,
thus
effectively
preventing
cancer.
However,
no
comprehensive
reviews
summarizing
effects
mechanisms
on
treatment
Therefore,
this
review
described
inhibitory
active
peptides
from
different
plant
protein
sources
Additionally,
we
summarized
advantages
preparation
protein-derived
anticancer
peptide-encapsulated
nanoparticles
their
This
provides
scientific
basis
understanding
offers
guidance
development
adjuvants
enriched
with
these
peptides.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Март 6, 2025
Whole-body
bone
scan
(WBS)
is
usually
used
as
the
effective
diagnostic
method
for
early-stage
and
comprehensive
metastases
of
breast
cancer.
WBS
images
with
cancer
metastasis
have
characteristics
low
resolution,
small
foreground,
multiple
lesions,
hindering
widespread
application
deep
learning-based
models.
Automatically
detecting
a
large
number
densely
lesions
on
low-resolution
remains
challenge.
We
aim
to
develop
unified
framework
based
images.
propose
novel
detection
detect
Considering
difficulties
feature
extraction
caused
by
resolution
we
innovatively
plug-and-play
position
auxiliary
module
fusion
enhance
ability
global
information
extraction.
In
order
accurately
in
WBS,
designed
self-attention
transformer-based
target
head.
This
retrospective
study
included
512
patients
from
Peking
Union
Medical
College
Hospital.
The
data
type
whole-body
image.
For
our
study,
ratio
training
set,
validation
set
test
about
6:2:2.
benchmarks
are
four
representative
baselines,
SSD,
YOLOR,
Faster_RCNN_R
Scaled-YOLOv4.
performance
metrics
Average
Precision
(AP),
Recall.
results
obtained
through
proposed
were
assessed
using
Bonferroni-adjusted
Wilcoxon
rank
test.
significant
level
adjusted
according
different
comparisons.
conducted
extensive
experiments
ablation
studies
private
dataset
public
scans
West
China
Hospital
validate
effectiveness
generalization.
Experiments
evaluate
method.
First,
compared
network
architectures,
AP
55.0
±
6.4%
(95%
confidence
intervals
(CI)
49.9–60.1%,
$$p<0.05$$
),
which
improved
45.2%
SSD
baseline
9.8
2%
CI
8.1–11.4%).
metric
recall,
achieved
average
54.3
4.2%
50.9–57.6%,
has
recall
values
49.01%
model
5.2
12.7%
10–21.3%).
Second,
studies.
On
dataset,
adding
head
will
increase
14.03%
(from
33.3
47.6
4.4%)
19.3%
52.6
6.1%),
respectively.
addition,
generalization
was
also
verified
BS-80K
Extensive
experimental
demonstrated
superiority
To
best
knowledge,
work
first
attempt
developing
automatic
detector
considering
unique
foreground
Our
tailored
can
be
clinical
decision
support
tool
early
decision-making
metastases.
Current Oncology,
Год журнала:
2025,
Номер
32(4), С. 226 - 226
Опубликована: Апрель 11, 2025
Bone
metastases
are
a
major
concern
in
cancer
management
since
they
significantly
contribute
to
morbidity
and
mortality.
Metastatic
lesions,
commonly
arising
from
breast,
prostate,
lung,
kidney
cancers,
affect
approximately
25%
of
patients,
leading
severe
complications
such
as
pain,
fractures,
neurological
deficits.
This
narrative
review
explores
contemporary
approaches
bone
metastases,
emphasizing
multidisciplinary
strategy
the
evolving
concept
oligometastatic
disease.
Oligometastases,
defined
by
limited
metastatic
spread
(1–5
lesions),
offer
potential
window
for
curative
treatment
through
aggressive
interventions,
including
stereotactic
ablative
radiotherapy
resection
surgery.
Tumor
boards,
integrating
systemic
therapies
with
local
crucial
optimize
treatment.
Despite
promising
results,
gaps
remain
defining
optimal
sequences
refining
patient
selection
criteria.
Future
research
should
focus
on
personalized
approaches,
leveraging
biomarkers
advanced
imaging
enhance
outcomes
quality
life
patients
metastases.
Pharmaceutics,
Год журнала:
2025,
Номер
17(5), С. 603 - 603
Опубликована: Май 2, 2025
Bone
metastases
are
a
prevalent
and
debilitating
consequence
of
various
cancers,
including
breast
prostate
carcinomas,
which
significantly
compromise
patient
quality
life
due
to
pain,
fractures,
other
skeletal-related
events
(SREs).
This
review
examines
the
pathophysiology
bone
metastases,
emphasizing
role
microenvironment
in
tumor
progression
through
mechanisms
such
as
osteotropism
dysregulated
remodeling
cycle.
The
primary
focus
is
on
emerging
nano-drug
delivery
systems
(DDS)
designed
target
improve
therapeutic
index
anticancer
agents.
Current
treatments,
mainly
comprising
bisphosphonates
radiotherapy,
provide
palliative
benefits
but
often
have
limited
efficacy
significant
side
effects.
Innovative
strategies,
bisphosphonate-conjugated
nanoparticles
targeted
therapies
that
utilize
unique
marrow
niche,
explored
for
their
potential
enhance
drug
accumulation
at
metastatic
sites
while
minimizing
systemic
toxicity.
These
approaches
include
use
liposomes,
polymeric
nanoparticles,
inorganic
can
be
functionalized
exploit
biological
barriers
within
microenvironment.
also
discusses
challenges
future
directions
nano-DDS
clinical
settings,
need
multidisciplinary
research
effectively
integrate
these
technologies
into
standard
care
protocols.
Cancer Cell International,
Год журнала:
2025,
Номер
25(1)
Опубликована: Май 25, 2025
Osteosarcoma
(OS),
chondrosarcoma
(CHS),
and
Ewing
sarcoma
(EWS)
are
the
main
types
of
bone
cancer
(BC).
OS
is
most
common
BC
in
this
group.
It
children
older
people,
especially
their
long
bones.
Treatments
for
sarcomas
tumors
have
slowly
improved,
so
researchers
began
looking
into
additional
alternative
approaches
to
standard
therapies.
Therefore,
ability
precisely
manipulate
metallic
nanoparticles
(MNPs)'
form,
size,
charge,
surface
modification
makes
them
very
useful
treating
cancer.
However,
due
biocompatibility
possible
toxicity
MNPs,
MNP
has
limits
clinical
use
BC.
green
synthesis
MNPs
achieved
by
bio-reducing
ions,
which
results
creation
NPs,
using
living
entities
or
extracts.
Green
derived
from
natural
sources
provide
a
secure
environmentally
responsible
solution.
Benefits
include
tailored
medicine
delivery
biocompatibility.
reduce
damage
healthy
cells
while
improving
targeting
cells.
In
study,
we
reviewed
how
different
synthesized
methods
can
help
treat
various
This
work
usual
way
making
BC,
problems
with
benefits
future
uses
synthetic
